Detect prostate cancer likelihood from blood with 94% accuracy.

For decades, prostate cancer screening has relied on tools that are helpful – but imperfect. Elevated PSA levels, unclear imaging, and invasive biopsies often lead men down stressful and costly paths, even when cancer isn’t present. Oxford BioDynamics is addressing that gap with a clinically validated blood test that looks beyond traditional markers to identify a distinct molecular signal associated with prostate cancer. By adding clarity where uncertainty once lived, this approach helps clinicians decide who truly needs further testing – and who doesn’t.

In this segment, a practicing urologist shares how clearer information can change conversations, reduce unnecessary biopsies, and help patients move forward with greater confidence. The story is not about replacing existing tools, but about strengthening them – making prostate cancer detection more accurate, more efficient, and more humane. At its core, this is a story about trust: giving patients information they can understand, and giving doctors data that helps them act with confidence.